Skip to main content
Download PDF

Apolipoprotein E and clusterin inhibit the early phase of amyloid-β aggregation in an in vitro model of cerebral amyloid angiopathy

Acta Neuropathologica Communications volume 7, Article number: 12 (2019) Cite this article

Abstract

Sporadic cerebral amyloid angiopathy (CAA) is characterized by cerebrovascular amyloid-β (Aβ) deposition, which leads to lobar hemorrhage and dementia. Biological molecules affecting the development of CAA have not been fully characterized. In this study, we performed proteome analysis of biopsied leptomeningeal and cortical vessels obtained from 6 CAA patients and 5 non-CAA patients who underwent surgery for large lobar hemorrhages. We found that 6 proteins, including Aβ, apolipoprotein E (apoE), clusterin (CLU), albumin, complement C4 and vitronectin were significantly upregulated in the vessels of CAA patients as compared to non-CAA patients. ApoE and CLU were found in all CAA patients. We next examined the effects of apoE and CLU on the early phase of Aβ aggregation, using a simple yet powerful in vitro model of CAA, which recapitulates the intramural periarterial drainage pathway model. We found that physiological concentrations of apoE and CLU delayed the initiation time of amyloid growth kinetics in a concentration-dependent manner. These data indicate that apoE and CLU may act as extracellular chaperones to inhibit Aβ amyloid deposition in CAA.

Introduction

Sporadic cerebral amyloid angiopathy (CAA) is characterized by amyloid-β (Aβ) deposition in the cortical and leptomeningeal arteries, which leads to lobar hemorrhage, infarction, encephalopathies and dementia [40, 41]. Recently, several groups reported that various proteins are deposited with Aβ in the vessel walls of postmortem, autopsied CAA patients [14, 17, 20]. Apolipoprotein E (apoE), clusterin (CLU, also called apolipoprotein J. apoJ), serum amyloid-P component, tissue inhibitor of metalloproteinases-3, sushi repeat-containing protein 1 (SRPX1) and other proteins are the major Aβ-associated proteins in the vessel walls of CAA patients. However, the effects of these proteins on the development of CAA are not clear except for SRPX1, which may enhance the cerebrovascular degeneration induced by Aβ [17].

In this study, we first performed proteome analysis of biopsied leptomeningeal and cortical vessels obtained from 6 CAA patients and 5 non-CAA patients who underwent surgery for large lobar hemorrhages [18]. We found that expression of apoE and CLU is significantly increased in the vessels of acute-onset, symptomatic CAA patients as compared to non-CAA patients. Next, we examined the effects of apoE and CLU on the early phase of Aβ aggregation, using a powerful, physiologically relevant in vitro model of CAA [10]. This model was previously established to test the hypothesis that intramural periarterial drainage (IPAD) flow carries Aβ to the vascular basement membrane (BM), which may trap Aβ and induce amyloid fibril formation in vivo [1, 22].

Materials and methods

Materials

Aβ(1–40) (code 4307-v, trifluoroacetic salt, lyophilized from dimethyl sulfoxide solution) was purchased from Peptide Institute Inc. (Osaka, Japan). Human serum albumin (HSA) (code 70024–90-7, A8763) was purchased from Sigma. Matrigel (Phenol Red free, code 356237) was purchased from Becton-Dickinson and Co. (NJ, USA). NHS-activated Sepharose 4 Fast Flow (code 17–0906-01) was purchased from GE Healthcare UK Ltd. Recombinant human apolipoprotein E3 (apoE3) (code 010–20261) and apoE4 (code 017–20271) were purchased from Wako (Osaka, Japan). Human CLU was purified from human serum as described previously [29].

Patients and specimens for proteome analysis

We recently reported the prevalence of CAA in patients who underwent surgery in our hospital for large lobar hemorrhages, i.e., supratentorial bleeding expanding from the cerebral cortex to subcortical white matter [18]. To diagnose CAA, we examined biopsied cortical tissues around hematomas with Congo-red and anti-Aβ staining. The same biopsied tissue was used for a series of histopathological and immunohistochemical staining to diagnose CAA and for the subsequent proteome analysis. We examined a cohort of 24 CAA patients and 5 non-CAA patients. Of 24 CAA patients, 16 patients (66.7%) had severe (Grade 4) CAA based on the pathological grading system for CAA developed by Greenberg et al. [9].

From this cohort, we selected 6 CAA patients (all Grade 4) and 4 non-CAA patients for which sufficient amounts of pathological specimens were available for the subsequent proteome analysis (Table 1). To increase the patient number, we added one additional non-CAA patient who underwent surgery in our hospital (B-1 in Table 1).

Table 1 Profiles of cases of CAA and non-CAA patients analysed by LMD-LC-MS/MS
Full size table

Protein extraction and proteome analysis

Protein extraction and proteome analysis were performed with liquid chromatography-tandem mass spectrometry (LC-MS/MS), essentially as described elsewhere [17]. Briefly, 4 μm thick slices of formalin-fixed and paraffin-embedded brain biopsy samples were placed on membrane slides (Leica Microsystems, Wetzlar, Germany). Sections were air-dried and then melted, deparaffinized, and stained with Congo red combined with nuclear counterstaining with hematoxylin. In the CAA group, Congo red-positive leptomeningeal and cortical vessels, which were identified using the bright-field setting, were isolated via laser capture microdissection (LCM) (LMD7000; Leica Microsystems, Wetzlar, Germany) (Table 1), then analysed using nano-flow reversed-phase LC–MS/MS (LTQ Velos Pro; Thermo Fisher Scientific). In the non-CAA group, leptomeningeal and cortical vessels, which were identified using the bright-field setting, were isolated via LCM. In both groups, we didn’t discriminate arteries from veins. The relative abundances of the identified molecules were obtained using the normalized spectral abundance factor (NSAF) [27] (Table 2).

Table 2 Proteins in the cerebral blood vessels of CAA patients vs. non-CAA patients
Full size table

Kinetic analysis of the seeded aggregation of Aβ(1–40) amyloid fibrils

In this paper, we used only Aβ(1–40) because Aβ(1–40) is the predominant Aβ species deposited in the vessels of CAA patients [40, 41]. Aβ(1–40) amyloid fibrils (fAβ(1–40)) were first formed by incubating 1.0 ml of the reaction mixture containing 50 μM Aβ(1–40), 50 mM sodium phosphate, pH 7.5, 100 mM NaCl phosphate buffered saline (PBS), and 0.05% NaN3 at 37 °C for 1 week. Subsequently, a reaction mixture containing 2.5 μg/ml fAβ(1–40), 5 μM Aβ(1–40), 0–0.5 μM apoE3 or 0–1.0 μM CLU, 0.3 mg/ml (4.5 μM) HSA, PBS, and 5 μM thioflavin T (ThT) was incubated at 37 °C without shaking in a 96-well plate (code HSP9666, Bio Rad, USA) sealed with a sealing film (code 676070, Greiner Bio-One GmbH, Frickenhausen, Germany). ThT fluorescence was measured every 5 min for 2 h using a Safire2 microplate fluorometer (TECAN, Austria) with excitation at 445 nm and emission at 490 nm.

Analysis of the effects of ApoE and CLU on the length of the lag phase of Aβ(1–40) amyloid aggregation

In this paper, we utilized a previously established powerful in vitro model of CAA [10] to analyse the effects of apoE and CLU on the length of the lag phase of Aβ(1–40) amyloid aggregation, essentially as described in [10]. Briefly, we reconstituted an artificial BM on the surface of NHS-activated Sepharose 4 Fast Flow beads by conjugating Matrigel to their surface (Fig. 1). Matrigel-coated beads were then incubated with 5 μM Aβ(1–40), 0.3 mg/ml (4.5 μM) HSA, PBS, 0.05% NaN3 (PBS-NaN3), 5 μM ThT, and 0–0.5 μM apoE3/E4 or 0–1.0 μM CLU at 37 °C in a clear microtiter plate module (Nunc, F8 Immuno module, Maxisorp, code: 468667) in which the air water interface was completely removed. The plate was gently rotated at 1 rpm. As these beads slowly sink from the top to the bottom of a well, their surfaces are exposed to the relative countercurrent of the reaction mixture, which mimics the IPAD flow in vitro.

Fig. 1
figure1

Schematic representation of the in vitro model of CAA used in this study. Sepharose 4 Fast Flow beads are highly cross-linked 4% agarose beads with a mean diameter of 90 μm. The pore sizes of the beads may be similar to the sizes of BM components, resulting in the conjugation of BM components onto the surface of beads. During the rotation, beads are exposed to the relative countercurrent of the reaction mixture, which mimics intramural periarterial drainage (IPAD) flow in vitro and enhances the interaction of Aβ with surface-bound BM components leading to Aβ aggregation. HSA: human serum albumin (modified from Fig. 6 of [10])

Full size image

The ThT-reactive aggregates in the microtiter wells were visualized with a fluorescence microscope (MVX10, Olympus Corporation, Tokyo, Japan) equipped with CFP filter sets (excitation 425–445 nm, emission 460–510 nm). Then the fluorescence images recorded for 1 s with a DP 72 digital camera (Olympus Corporation, Tokyo, Japan). We chose the first time point at which ThT-reactive aggregates were detected as the initiation time for fibril growth kinetics. The preceding lag phase is the time during which nuclei, on-pathway oligomers and protofibrils are successively formed prior to the subsequent rapid fibril growth phase. In most cases, one observer (Y.E.) mainly determined the initiation time by visual inspection of recorded images. In the specific cases of data shown in Figs. 4, 5 and 6, another observer (R.N.) re-determined the initiation time and similar results were obtained (data not shown).

To monitor Aβ(1–40) amyloid formation in a conventional way, we also measured the ThT fluorescence with a Safire2 microplate fluorometer (TECAN, Austria). For the kinetic analysis, data obtained with a fluorescence microscope was used because microscopic detection of fluorescent spots on the Sepharose-beads often preceded the increase in fluorescence measured by fluorometry by 12 to 24 h (data not shown).

We then measured the duration of the lag phase for each well using the Kaplan-Meier survival method and the initiation time of amyloid growth kinetics as the event of interest (Fig. 2). In this assay, the reaction mixture in which ThT-reactive aggregates have not yet been detected is considered as “surviving”. Thus, the survival rate corresponds to the percentage of the reaction mixtures in which ThT-reactive aggregates have not yet been detected. The statistical significance was compared by the log rank test, followed by pair to pair multiple comparisons using the Holm-Sidak method. For the calculation, we excluded any wells in which air bubbles emerged before the detection of ThT-reactive aggregates. The survival analysis was performed with SigmaPlot 12 (Systat Software, Inc. CA). The differences between the two groups were considered significant if P values were less than 0.05.

Fig. 2
figure2

Kaplan-Meier survival method used to evaluate the duration of the lag phase of Aβ aggregation. The kinetics were analysed by the Kaplan-Meier survival method using the initiation time of amyloid growth kinetics as the event of interest. Aβ(1–40) was incubated with Matrigel-coated Sepharose beads as described in Materials and Methods. The appearance of ThT-reactive aggregates was monitored with a fluorescence microscope. The first time at which ThT-reactive aggregates were detected was set as the initiation time of amyloid growth. When ThT-reactive aggregates are detected in 1 well of 5, the “survival rate” is recorded as having decreased from 1.0 to 0.8. Similarly, if ThT-reactive aggregates are then detected in 1 of the remaining 4 wells, then the “survival rate” is recorded as having decreased from 0.8 to 0.6. Thus, the slower the kinetics of early phase Aβ aggregation, the more time is required to reach a “survival” value of zero. This model was used to evaluate the concentration-dependent effects of apoE and CLU on the kinetics of early phase Aβ aggregation

Full size image

Results

Profiles of CAA and non-CAA patients

Table 1 shows the profiles of the CAA and non-CAA patients analysed by LCM-LC-MS/MS. The 6 CAA patients were from 63 to 80 years old (mean ± SD 72.2 ± 6.9). Compatible with the female predominance in CAA patients [41], all 6 patients were female and had grade 4 CAA. Three of the 6 patients had hypertension and took antihypertensive agents. No patients took anticoagulant or antiplatelet drugs. Two patients were positive for strictly lobar microbleeding as evaluated by T2*-weighted magnetic resonance imaging (MRI). The ages of the 5 non-CAA patients were from 61 to 83 years old (mean ± SD 70.8 ± 8.4). Four patients were male, and 1 patient was female. We found no female predominance in non-CAA patients. Three of the 5 patients had hypertension and only 1 took antihypertensive agents. Thus, it is reasonable to consider that for these 3 patients, the etiology of hemorrhage may be hypertension. As for the remaining 2 patients, although we excluded CAA as an etiology of hemorrhage, we did not definitely identify the etiology of hemorrhage. No patients took anticoagulant or antiplatelet drugs. No patients were positive for microbleeding as evaluated by T2*-weighted MRI.

Proteome analysis

As shown in Table 2, 6 proteins, including Aβ, apoE, CLU, albumin, complement C4 and vitronectin were significantly upregulated in the cerebral blood vessels of CAA patients as compared to non-CAA patients. Aβ was found only in CAA patients. Albumin was found in all patients of CAA and non-CAA groups. ApoE and CLU were found in all patients of the CAA group but were found in only 1 patient of the non-CAA group (20%). Both apoE and CLU are representative amyloid signature proteins [2]. Thus, in the following study, we analysed the effects of apoE and CLU on Aβ amyloid formation in two different in vitro systems.

The effects of apoE and CLU on the seeded aggregation of Aβ(1–40) amyloid fibrils

We first used the conventional in vitro experimental system with an air-water interface to examine the effects of apoE and CLU on the seeded aggregation of Aβ(1–40) amyloid. In the absence of apoE and CLU, ThT fluorescence increased rapidly with no lag time to reach a plateau at around 2 h after initiation of the reaction (Fig. 3), consistent with the first-order kinetic model of amyloid fibril growth in vitro [25]. As shown in Fig. 3, both apoE and CLU concentration-dependently inhibited the formation of Aβ amyloid in this system.

Fig. 3
figure3

Effects of apoE and CLU on the seeded aggregation of fAβ(1–40) in vitro. a The reaction mixture containing 2.5 μg/ml fAβ(1–40), 5 μM Aβ(1–40), 0 (●), 0.05 (○), 0.1 (■), 0.2 (□), 0.5 μM (▲) apoE3, 0.3 mg/ml HSA, PBS, and 5 μM ThT was incubated at 37 °C without shaking in a 96-well plate. b The reaction mixture containing 2.5 μg/ml fAβ(1–40), 5 μM Aβ(1–40), 0 (●), 0.05 (○), 0.25 (■), 0.5 (□), 1.0 μM (▲) CLU, 0.3 mg/ml HSA, PBS, and 5 μM ThT was incubated at 37 °C without shaking in a 96-well plate. ThT fluorescence was monitored as described in Materials and Methods. Points and bars represent mean + S.D. of 6 replicates. This data is representative of three independent experiments

Full size image

The effects of apoE and CLU on the duration of the lag phase of Aβ aggregation in an in vitro model of CAA

As shown in Fig. 4, apoE3 delayed the initiation time of fibril growth kinetics in a concentration-dependent manner, indicating that apoE3 inhibited early phase Aβ aggregation. Importantly, apoE3 significantly inhibited the early phase aggregation of Aβ when at a concentration that is physiological in the cerebrospinal fluid (CSF) (1.8–4.0 μg/ml or 0.05–0.12 μM) [28]. CLU also concentration-dependently delayed the initiation time of fibril growth kinetics (Fig. 5), significantly inhibiting the early phase of Aβ aggregation when at a concentration that is physiological in CSF (3.5–5.7 μg/ml or 0.07–0.11 μM) [33]. As shown in Fig. 6, the same concentrations of apoE3 and E4 exhibited no significant isoform-dependent difference in their ability to inhibit the early phase aggregation of Aβ.

Fig. 4
figure4

Effect of apoE3 on the kinetics of early phase aggregation of Aβ(1–40). The reaction mixture containing 5 μM Aβ(1–40), 10 μl suspensions of Matrigel-coated beads, 0.3 mg/ml HSA, PBS-NaN3, 5 μM ThT, and 0 to 0.5 μM apoE3 was incubated at 37 °C with rotation at 1 rpm in the absence of an air-water interface (30 replicate wells in each case). As a positive control, the reaction mixture containing 5 μM Aβ(1–40), 0.3 mg/ml HSA, PBS-NaN3, and 5 μM ThT was also incubated at 37 °C with rotation at 1 rpm in the presence of an air-water interface (12 replicate wells) (Air). The kinetics of early phase aggregation was analysed by the Kaplan-Meier survival method using the initiation time of fibril growth kinetics as the event of interest (see Fig. 2). The P value was less than 0.05 between all combinations. This data is representative of three independent experiments

Full size image
Fig. 5
figure5

Effect of CLU on the kinetics of early phase aggregation of Aβ(1–40). The reaction mixture containing 5 μM Aβ(1–40), 10 μl suspensions of Matrigel-coated beads, 0.3 mg/ml HSA, PBS-NaN3, 5 μM ThT, and 0 to 1.0 μM CLU was incubated at 37 °C with rotation at 1 rpm in the absence of an air-water interface (18 replicate wells in each case). As a positive control, the reaction mixture containing 5 μM Aβ(1–40), 0.3 mg/ml HSA, PBS-NaN3, and 5 μM ThT was also incubated at 37 °C with rotation at 1 rpm in the presence of an air-water interface (18 replicate wells) (Air). The kinetics of early phase aggregation was analysed by the Kaplan-Meier survival method using the initiation time of fibril growth kinetics as the event of interest (see Fig. 2). The P value was less than 0.05 between all combinations except for between 0.25 and 0.5 μM CLU. This data is representative of three independent experiments

Full size image
Fig. 6
figure6

Comparison of the effect of apoE3 with apoE4 on the kinetics of early-phase Aβ(1–40) aggregation. The reaction mixture containing 5 μM Aβ(1–40), 10 μl suspensions of Matrigel-coated beads, 0.3 mg/ml HSA, PBS-NaN3, 5 μM ThT, and 0 to 0.2 μM apoE3 or apoE4 was incubated at 37 °C with rotation at 1 rpm in the absence of an air-water interface (18 replicate wells in each case). As a positive control, the reaction mixture containing 5 μM Aβ(1–40), 0.3 mg/ml HSA, PBS-NaN3, and 5 μM ThT was also incubated at 37 °C with rotation at 1 rpm in the presence of an air-water interface (18 replicate wells) (Air). The kinetics of early phase aggregation was analysed by the Kaplan-Meier survival method using the initiation time of fibril growth kinetics as the event of interest (see Fig. 2). The P value was less than 0.05 for all pair-wise comparisons except those between apoE3 and apoE4 when both were at either 0.05 μM or 0.2 μM. This data is representative of three independent experiments

Full size image

We previously reported that under these same experimental conditions, 0.1–1.0 mg/ml (1.5–15.1 μM) HSA has no significant effect on the early phase of Aβ aggregation [10]. Thus, we conclude that apoE and CLU specifically and concentration-dependently inhibit the early phase of Aβ aggregation.

Discussion

In this study, we first performed proteome analysis of the Aβ-deposited leptomeningeal and cortical vessels (Tables 1 and 2). To the best of our knowledge, this is the first report of the proteome analysis of vessels biopsied from living symptomatic, clinical CAA patients. In previously published reports, proteome analysis was performed with leptomeningeal vessels obtained from postmortem, autopsied cases, in which Aβ deposition was histopathologically confirmed [14, 17, 20]. Although CAA is known to be more severe in posterior brain regions compared to anterior brain regions [41] and postmortem proteome analysis was performed using the vessels derived from occipital lobes [14, 17, 20], frontal lobes were involved in 3 CAA patients and parietal and temporal lobes were involved in other 3 CAA patients (Table 1). This difference in the brain regions from which the vessels were obtained may affect the results of proteome analysis (Table 2 vs. [14, 17, 20]). For example, this may explain why we found no significant upregulation of tissue inhibitor of metalloproteinases-3 (Table 2), in contrast to the finding of Manousopoulou et al. [20]. Additionally, the discrepancy in male/female ratio between CAA and non-CAA patients (male/female: 0/6 and 4/1, respectively) may also affect the results of our proteome analysis. Both apoE and CLU are representative signature proteins in various types of systemic amyloidosis [2]. Thus, it is worth noting that apoE and CLU are representative Aβ-associated proteins in the vessel walls of clinical CAA cases (Table 2), as well as in those of pathological CAA cases [14, 17, 20].

Carare and coworkers proposed the IPAD pathway model [1, 22, 34]. This model constitutes that instead of the conventional lymphatics, interstitial fluid and solutes are drained from the brain parenchyma to cervical lymph nodes along BMs in the walls of cerebral capillaries and tunica media of leptomeningeal arteries. Through this pathway, Aβ peptides, especially Aβ(1–40) produced by cortical neurons are carried away from the brain parenchyma [1, 22]. Reduced Aβ trafficking through this pathway may result in the aggregation of Aβ amyloid in the cerebrovascular BMs, leading to the manifestation of pathological as well as clinical CAA [41]. However, the driving mechanisms of this pathway and the molecules affecting the trafficking and aggregation of Aβ in this pathway are not fully understood [41, 43]. We previously established a simple yet powerful in vitro model of CAA, which recapitulates the IPAD flow draining Aβ and other solutes, as well as the vascular BM as a scaffold for Aβ aggregation in vitro [10]. To the best of our knowledge, this is the first, and the only in vitro system which recapitulates the pathogenesis of CAA in a physiologically relevant manner (Fig. 1). First, we completely removed the air-water interface, which is a hydrophobic-hydrophilic interface that potently induces protein denaturation and amyloid formation [21]. Complete removal of the air-water interface makes it possible to detect weak effects of BM molecules on the induction of amyloid formation in vitro. Second, we reduced Aβ concentration as low as possible (5 μM) to inhibit the spontaneous aggregation of Aβ in the reaction mixture. We also added HSA (4.5 μM) to mimic the CSF environment. Finally, we reproduced the IPAD flow in vitro by gently rotating the plate at 1 rpm. As Matrigel-coated beads slowly sink from the top to the bottom of a well, their surfaces are exposed to the relative countercurrent of the reaction mixture to induce the interaction of Aβ with BM molecules. Using this model, we have demonstrated that apoE and CLU inhibit the early phase aggregation of Aβ in vitro (Figs. 4 and 5).

Although apoE is considered as a key player in the pathogenesis of Alzheimer’s disease (AD) and CAA [16, 32], the effects of apoE on the aggregation of Aβ in vitro and in vivo are controversial. While some groups reported that apoE accelerates Aβ fibril formation in vitro [31, 35], we and other groups reported that apoE inhibits Aβ aggregation in vitro [6, 8, 15, 24, 37]. These opposite effects may be partly due to the difference in the concentrations of Aβ used in each experiment. We previously reported that apoE may inhibit or enhance Aβ amyloid fibril formation in a concentration-dependent manner [24]. When 50 μM Aβ(1–40) was incubated with 50–500 nM apoE, apoE dose-dependently inhibited Aβ amyloid fibril formation. In contrast, when 300 μM Aβ(1–40) was incubated with 3 μM apoE, apoE slightly enhanced Aβ aggregation. Similarly, while some groups reported that apoE promotes Aβ amyloid deposition in vivo [12], other groups showed that apoE delays Aβ amyloid deposition in vivo [4, 7, 13, 15, 32]. LaDu and coworkers produced EFAD mice, which are a tractable familial AD-transgenic (FAD-Tg) mouse model expressing human APOE rather than mouse APOE [32]. Consistent with our data (Fig. 4), they showed that introduction of human APOE to EFAD mice delays extracellular Aβ accumulation (not only plaque deposition but also CAA) from ~ 2 to 6 months compared with the control 5xFAD mice expressing mouse APOE [32]. They suggested that the mouse apoE is structurally and functionally distinct from human apoE.

The pathogenesis of AD and CAA is affected by apoE isoform-dependently [16, 32]. Robust data confirmed that ε4 allele of APOE is not only the risk factor of AD but also that of nonhemorrhagic-type CAA [3, 16, 32, 40]. In contrast, while the ε2 allele of APOE is protective for the manifestation of AD, it is a risk factor of hemorrhagic-type CAA [3, 16, 32, 40]. Tai et al. reported that the ability of human APOE to delay the extracellular Aβ accumulation in EFAD mice was in the order of 5xFAD < E4FAD < E3FAD ≤ E2FAD [32]. Consistent with this in vivo observation, Hori et al. reported that the in vitro conversion of Aβ protofibrils to fibrils progressed more slowly upon co-incubation with apoE2 or apoE3 as compared to the case with apoE4 [15]. In contrast, we found that the inhibitory effect of apoE3 on the kinetics of early phase Aβ aggregation was not significantly different from that of apoE4 (Fig. 6). It is hypothesized that apoE affects the pathogenesis of AD and CAA through a variety of mechanisms, including the effects on Aβ aggregation, Aβ transport and clearance from the interstitial/cerebrospinal fluid, and cellular metabolism of Aβ [16]. Thus, the linkage of ε4 allele of APOE to the manifestation of nonhemorrhagic-type CAA might result from mechanisms other than the direct effects of apoE on Aβ aggregation. Future studies are eagerly awaited to resolve this issue.

The pathogenesis of AD and CAA is affected by CLU [11, 36, 38]. Wilson and coworkers reported that CLU inhibits Aβ aggregation in vitro [26, 39, 42]. Consistent with our data (Fig. 5), Yerbury et al. reported that CLU significantly inhibits Aβ amyloid fibril formation at a molar ratio of CLU:Aβ =1:100 [42]. The effects of CLU on the aggregation of Aβ in vivo are controversial. While DeMattos et al. reported that CLU promotes amyloid plaque formation in vivo [5], Qi et al. reported that CLU reduces Aβ plaques as well as the severity of CAA in vivo [30]. Interestingly, DeMattos et al. reported that apoE−/−/Clu−/− PDAPP mice had both earlier onset and marked increase of Aβ deposition, suggesting that apoE and CLU cooperatively lower the Aβ level and suppress deposition [4]. Importantly, Wojtas et al. found a marked decrease in cortical plaque deposition but an equally striking increase in CAA in the brains of APP/PS1;Clu−/− mice as compared to Clu+/+ mice. They proposed that CLU facilitates Aβ clearance along the IPAD pathway by preventing binding of Aβ to cerebrovascular BMs [36]. This model is consistent with our data indicating that CLU acts as an extracellular chaperone to prevent the manifestation of CAA.

Finally, we consider how apoE and CLU inhibit amyloid formation in vitro. Based on a nucleation-dependent polymerization model [19, 23], we confirmed that apoE and CLU inhibit the early phase of Aβ aggregation (Figs. 4 and 5) as well as the seeded aggregation of Aβ amyloid fibrils (Fig. 3). Hori et al. reported that apoE interacts with Aβ protofibrils in the order of apoE2 = E3 > E4, leading to the inhibition of the conversion of Aβ protofibrils to fibrils [15]. Narayan et al. reported that CLU binds Aβ oligomers formed during the aggregation of Aβ monomers, thereby inhibiting the further growth of these oligomers into mature amyloid fibrils [26]. These reports may indicate that apoE and CLU interact with Aβ nuclei/on-pathway oligomers formed on the Matrigel-coated beads, leading to the inhibition of the successive aggregation of these species into amyloid fibrils (Figs. 4 and 5). Additionally, we previously reported that, like CLU, apoE inhibits the in vitro growth of Aβ amyloid fibrils by binding and sequestering Aβ monomers [24] (Fig. 3).

Conclusions

We performed proteome analysis with the vessels biopsied from symptomatic, clinical CAA patients and confirmed that the expression of both apoE and CLU are significantly increased in the vessels of CAA patients as compared to non-CAA patients. Next, we used a unique in vitro model of CAA to confirm that apoE and CLU specifically inhibit the early phase of Aβ aggregation on the surface of BM-coated beads. The interaction of Aβ with vascular BMs may be a promising therapeutic target for CAA. Future studies are essential to develop the therapeutics for CAA.

Abbreviations

AD:

Alzheimer’s disease

apoE:

apolipoprotein E

Aβ:

amyloid-β

BM:

Basement membrane

CAA:

Cerebral amyloid angiopathy

CLU:

Clusterin

CSF:

Cerebrospinal fluid

fAβ(1–40):

Aβ(1–40) amyloid fibrils

HSA:

Human serum albumin

IPAD:

Intramural periarterial drainage

LCM:

Laser capture microdissection

LC-MS/MS:

Liquid chromatography-tandem mass spectrometry

MRI:

Magnetic resonance imaging

NSAF:

Normalized spectral abundance factor

PBS:

Phosphate buffered saline

SRPX1:

Sushi repeat-containing protein 1

ThT:

Thioflavin T

References

  1. 1.

    Albargothy NJ, Johnston DA, MacGregor-Sharp M, Weller RO, Verma A, Hawkes CA et al (2018) Convective influx/glymphatic system: tracers injected into the CSF enter and leave the brain along separate periarterial basement membrane pathways. Acta Neuropathol 136(1):139–152

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  2. 2.

    Brambilla F, Lavatelli F, Di Silvestre D, Valentini V, Palladini G, Merlini G et al (2013) Shotgun protein profile of human adipose tissue and its changes in relation to systemic amyloidoses. J Proteome Res 12(12):5642–5655

    CAS  PubMed  Article  Google Scholar 

  3. 3.

    Charidimou A, Martinez-Ramirez S, Shoamanesh A, Oliveira-Filho J, Frosch M, Vashkevich A et al (2015) Cerebral amyloid angiopathy with and without hemorrhage: evidence for different disease phenotypes. Neurology 84(12):1206–1212

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  4. 4.

    DeMattos RB, Cirrito JR, Parsadanian M, May PC, O'Dell MA, Taylor JW et al (2004) ApoE and clusterin cooperatively suppress Aβ levels and deposition: evidence that apoE regulates extracellular Aβ metabolism in vivo. Neuron 41(2):193–202

    CAS  PubMed  Article  Google Scholar 

  5. 5.

    DeMattos RB, O'dell MA, Parsadanian M, Taylor JW, Harmony JA, Bales KR et al (2002) Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 99(16):10843–10848

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  6. 6.

    Evans KC, Berger EP, Cho CG, Weisgraber KH, Lansbury PT Jr (1995) Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. Proc Natl Acad Sci U S A 92(3):763–767

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  7. 7.

    Fagan AM, Watson M, Parsadanian M, Bales KR, Paul SM, Holtzman DM (2002) Human and murine apoE markedly alters Aβ metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol Dis 9(3):305–318

    CAS  PubMed  Article  Google Scholar 

  8. 8.

    Garai K, Verghese PB, Baban B, Holtzman DM, Frieden C (2014) The binding of apolipoprotein E to oligomers and fibrils of amyloid-β alters the kinetics of amyloid aggregation. Biochemistry 53(40):6323–6331

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  9. 9.

    Greenberg SM, Vonsattel JP (1997) Diagnosis of cerebral amyloid angiopathy. Sensitivity and specificity of cortical biopsy. Stroke 28(7):1418–1422

    CAS  PubMed  Article  Google Scholar 

  10. 10.

    Hasegawa K, Ozawa D, Ookoshi T, Naiki H (2013) Surface-bound basement membrane components accelerate amyloid-β peptide nucleation in air-free wells: an in vitro model of cerebral amyloid angiopathy. Biochim Biophys Acta 1834(8):1624–1631

    CAS  PubMed  Article  Google Scholar 

  11. 11.

    Holtzman DM (2004) In vivo effects of apoE and clusterin on amyloid-β metabolism and neuropathology. J Mol Neurosci 23(3):247–254

    CAS  PubMed  Article  Google Scholar 

  12. 12.

    Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ et al (2000) Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 97(6):2892–2897

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  13. 13.

    Holtzman DM, Bales KR, Wu S, Bhat P, Parsadanian M, Fagan AM et al (1999) Expression of human apolipoprotein E reduces amyloid-β deposition in a mouse model of Alzheimer's disease. J Clin Invest 103(6):R15–R21

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  14. 14.

    Hondius DC, Eigenhuis KN, Morrema THJ, van der Schors RC, van Nierop P, Bugiani M et al (2018) Proteomics analysis identifies new markers associated with capillary cerebral amyloid angiopathy in Alzheimer's disease. Acta Neuropathol Commun 6(1):46

    PubMed  PubMed Central  Article  Google Scholar 

  15. 15.

    Hori Y, Hashimoto T, Nomoto H, Hyman BT, Iwatsubo T (2015) Role of apolipoprotein E in β-amyloidogenesis: isoform-specific effects on protofibril to fibril conversion of Aβ in vitro and brain Aβ deposition in vivo. J Biol Chem 290(24):15163–15174

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  16. 16.

    Huynh TV, Davis AA, Ulrich JD, Holtzman DM (2017) Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins. J Lipid Res 58(5):824–836

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  17. 17.

    Inoue Y, Ueda M, Tasaki M, Takeshima A, Nagatoshi A, Masuda T et al (2017) Sushi repeat-containing protein 1: a novel disease-associated molecule in cerebral amyloid angiopathy. Acta Neuropathol 134(4):605–617

    CAS  PubMed  Article  Google Scholar 

  18. 18.

    Lin CM, Arishima H, Kikuta KI, Naiki H, Kitai R, Kodera T et al (2018) Pathological examination of cerebral amyloid angiopathy in patients who underwent removal of lobar hemorrhages. J Neurol 265(3):567–577

    CAS  PubMed  Article  Google Scholar 

  19. 19.

    Lomakin A, Chung DS, Benedek GB, Kirschner DA, Teplow DB (1996) On the nucleation and growth of amyloid β-protein fibrils: detection of nuclei and quantitation of rate constants. Proc Natl Acad Sci U S A 93(3):1125–1129

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  20. 20.

    Manousopoulou A, Gatherer M, Smith C, Nicoll JAR, Woelk CH, Johnson M et al (2017) Systems proteomic analysis reveals that clusterin and tissue inhibitor of metalloproteinases 3 increase in leptomeningeal arteries affected by cerebral amyloid angiopathy. Neuropathol Appl Neurobiol 43(6):492–504

    CAS  PubMed  Article  Google Scholar 

  21. 21.

    Morinaga A, Hasegawa K, Nomura R, Ookoshi T, Ozawa D, Goto Y et al (2010) Critical role of interfaces and agitation on the nucleation of Aβ amyloid fibrils at low concentrations of Aβ monomers. Biochim Biophys Acta 1804(4):986–995

    CAS  PubMed  Article  Google Scholar 

  22. 22.

    Morris AW, Sharp MM, Albargothy NJ, Fernandes R, Hawkes CA, Verma A et al (2016) Vascular basement membranes as pathways for the passage of fluid into and out of the brain. Acta Neuropathol 131(5):725–736

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  23. 23.

    Naiki H, Gejyo F (1999) Kinetic analysis of amyloid fibril formation. Methods Enzymol 309:305–318

    CAS  PubMed  Article  Google Scholar 

  24. 24.

    Naiki H, Gejyo F, Nakakuki K (1997) Concentration-dependent inhibitory effects of apolipoprotein E on Alzheimer's β-amyloid fibril formation in vitro. Biochemistry 36(20):6243–6250

    CAS  PubMed  Article  Google Scholar 

  25. 25.

    Naiki H, Nakakuki K (1996) First-order kinetic model of Alzheimer's β-amyloid fibril extension in vitro. Lab Investig 74(2):374–383

    CAS  PubMed  Google Scholar 

  26. 26.

    Narayan P, Orte A, Clarke RW, Bolognesi B, Hook S, Ganzinger KA et al (2011) The extracellular chaperone clusterin sequesters oligomeric forms of the amyloid-β(1-40) peptide. Nat Struct Mol Biol 19(1):79–83

    PubMed  PubMed Central  Article  Google Scholar 

  27. 27.

    Paoletti AC, Parmely TJ, Tomomori-Sato C, Sato S, Zhu D, Conaway RC et al (2006) Quantitative proteomic analysis of distinct mammalian mediator complexes using normalized spectral abundance factors. Proc Natl Acad Sci U S A 103(50):18928–18933

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  28. 28.

    Pitas RE, Boyles JK, Lee SH, Hui D, Weisgraber KH (1987) Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B, E (LDL) receptors in the brain. J Biol Chem 262(29):14352–14360

    CAS  PubMed  Google Scholar 

  29. 29.

    Poon S, Rybchyn MS, Easterbrook-Smith SB, Carver JA, Pankhurst GJ, Wilson MR (2002) Mildly acidic pH activates the extracellular molecular chaperone clusterin. J Biol Chem 277(42):39532–39540

    CAS  PubMed  Article  Google Scholar 

  30. 30.

    Qi XM, Wang C, Chu XK, Li G, Ma JF (2018) Intraventricular infusion of clusterin ameliorated cognition and pathology in Tg6799 model of Alzheimer's disease. BMC Neurosci 19(1):2

    PubMed  PubMed Central  Article  Google Scholar 

  31. 31.

    Sanan DA, Weisgraber KH, Russell SJ, Mahley RW, Huang D, Saunders A et al (1994) Apolipoprotein E associates with β amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest 94(2):860–869

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  32. 32.

    Tai LM, Balu D, Avila-Munoz E, Abdullah L, Thomas R, Collins N et al (2017) EFAD transgenic mice as a human APOE relevant preclinical model of Alzheimer's disease. J Lipid Res 58(9):1733–1755

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  33. 33.

    van Dijk KD, Jongbloed W, Heijst JA, Teunissen CE, Groenewegen HJ, Berendse HW et al (2013) Cerebrospinal fluid and plasma clusterin levels in Parkinson’s disease. Parkinsonism Relat Disord 19(12):1079–1083

    PubMed  Article  Google Scholar 

  34. 34.

    Weller RO, Preston SD, Subash M, Carare RO (2009) Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease. Alzheimers Res Ther 1(2):6

    PubMed  PubMed Central  Article  Google Scholar 

  35. 35.

    Wisniewski T, Castaño EM, Golabek A, Vogel T, Frangione B (1994) Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol 145(5):1030–1035

    CAS  PubMed  PubMed Central  Google Scholar 

  36. 36.

    Wojtas AM, Kang SS, Olley BM, Gatherer M, Shinohara M, Lozano PA et al (2017) Loss of clusterin shifts amyloid deposition to the cerebrovasculature via disruption of perivascular drainage pathways. Proc Natl Acad Sci U S A 114(33):E6962–E6971

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  37. 37.

    Wood SJ, Chan W, Wetzel R (1996) Seeding of Aβ fibril formation is inhibited by all three isotypes of apolipoprotein E. Biochemistry 35(38):12623–12628

    CAS  PubMed  Article  Google Scholar 

  38. 38.

    Wyatt AR, Yerbury JJ, Dabbs RA, Wilson MR (2012) Roles of extracellular chaperones in amyloidosis. J Mol Biol 421(4–5):499–516

    CAS  PubMed  Article  Google Scholar 

  39. 39.

    Wyatt AR, Yerbury JJ, Ecroyd H, Wilson MR (2013) Extracellular chaperones and proteostasis. Annu Rev Biochem 82:295–322

    CAS  PubMed  Article  Google Scholar 

  40. 40.

    Yamada M (2015) Cerebral amyloid angiopathy: emerging concepts. J Stroke 17(1):17–30

    PubMed  PubMed Central  Article  Google Scholar 

  41. 41.

    Yamada M, Naiki H (2012) Cerebral amyloid angiopathy. Prog Mol Biol Transl Sci 107:41–78

    CAS  PubMed  Article  Google Scholar 

  42. 42.

    Yerbury JJ, Poon S, Meehan S, Thompson B, Kumita JR, Dobson CM et al (2007) The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures. FASEB J 21(10):2312–2322

    CAS  PubMed  Article  Google Scholar 

  43. 43.

    Zekonyte J, Sakai K, Nicoll JA, Weller RO, Carare RO (2016) Quantification of molecular interactions between apoE, amyloid-β (Aβ) and laminin: relevance to accumulation of Aβ in Alzheimer's disease. Biochim Biophys Acta 1862(5):1047–1053

    CAS  PubMed  Article  Google Scholar 

Download references

Acknowledgements

The authors thank N Takimoto and H Okada for excellent technical assistance.

Funding

This work was supported by JSPS KAKENHI Grant-in-Aid for Scientific Research (B) 16H05170 (H.N. and K.H.).

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Author information

Affiliations

  1. Second Department of Internal Medicine, University of Fukui, Fukui, 910-1193, Japan

    Yoshinori Endo, Tadanori Hamano & Yasunari Nakamoto

  2. Department of Molecular Pathology, Faculty of Medical Sciences, University of Fukui, Fukui, 910-1193, Japan

    Yoshinori Endo, Kazuhiro Hasegawa, Ryo Nomura & Hironobu Naiki

  3. Department of Neurosurgery, University of Fukui, Fukui, 910-1193, Japan

    Hidetaka Arishima & Ken-ichiro Kikuta

  4. Department of Neurology, Graduate School of Medical Sciences, University of Kumamoto, Kumamoto, 860-8556, Japan

    Taro Yamashita, Yasuteru Inoue, Mitsuharu Ueda & Yukio Ando

  5. School of Chemistry and Molecular Bioscience, Illawarra Health and Medical Research Institute (IHMRI), and Molecular Horizons Research Institute, University of Wollongong, Wollongong, New South Wales, 2522, Australia

    Mark R. Wilson

  6. Department of Aging and Dementia, University of Fukui, Fukui, 910-1193, Japan

    Tadanori Hamano

Authors
  1. Yoshinori Endo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazuhiro Hasegawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ryo Nomura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hidetaka Arishima
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ken-ichiro Kikuta
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Taro Yamashita
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yasuteru Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mitsuharu Ueda
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yukio Ando
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Mark R. Wilson
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Tadanori Hamano
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yasunari Nakamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Hironobu Naiki
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Study concept and design: YE, KH, HN. Acquisition analysis and interpretation of the data: YE, KH, RN, HA, KK, TY, YI, MU, YA, MRW, HN. Critical revision of the manuscript for intellectual content: KH, MRW, TH, YN, HN. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Hironobu Naiki.

Ethics declarations

Ethics approval and consent to participate

This study was approved by the Institutional Review Board of Fukui University Hospital.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Endo, Y., Hasegawa, K., Nomura, R. et al. Apolipoprotein E and clusterin inhibit the early phase of amyloid-β aggregation in an in vitro model of cerebral amyloid angiopathy. acta neuropathol commun 7, 12 (2019). https://doi.org/10.1186/s40478-019-0662-1

Download citation

Keywords

  • Cerebral amyloid angiopathy
  • Amyloid-β
  • Proteome analysis
  • Apolipoprotein E
  • Clusterin
  • Intramural periarterial drainage
  • Extracellular chaperone

Acta Neuropathologica Communications

ISSN: 2051-5960

Contact us